New Antibiotic Biotech Allecra Therapeutics Gets €15 Million Series A Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
Antibiotic biotech Allecra Therapeutics announced its creation amid fresh warnings about the rising number of bacteria that resist even the most potent antibiotics, and says it aims to use the cash to fund clinical development of a pair of antibiotics against multi-drug resistant, gram-negative bacteria.